CVM:NYE-CEL-SCI Corporation (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 7.87

Change

-0.31 (-3.79)%

Market Cap

USD 0.33B

Volume

0.79M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-0.59 (-0.66%)

USD203.75B 30.40 3.38
BHVN Biohaven Pharmaceutical Holdin..

-2.39 (-1.91%)

USD8.15B N/A N/A
RCUS Arcus Biosciences, Inc

+1.29 (+4.07%)

USD2.27B N/A N/A
MYOV Myovant Sciences Ltd

+0.50 (+2.45%)

USD1.87B N/A N/A
ADCT ADC Therapeutics SA

-0.47 (-2.09%)

USD1.76B -99,999.99 N/A
ZYME Zymeworks Inc

-0.84 (-2.27%)

USD1.71B 300.20 N/A
RFL Rafael Holdings, Inc

-1.42 (-2.73%)

USD0.92B N/A N/A
ANVS Annovis Bio, Inc

-3.89 (-3.50%)

USD0.77B -99,999.99 N/A
AMAM Ambrx Biopharma Inc

N/A

USD0.70B N/A N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90

ETFs Containing CVM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -32.50% 19% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.50% 19% F 3% F
Trailing 12 Months  
Capital Gain -39.55% 33% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.55% 33% F 3% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 29.22% 57% F 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.22% 57% F 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 36.32% 68% D+ 28% F
Risk Adjusted Return 80.44% 86% B 85% B
Market Capitalization 0.33B 64% D 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 11.15 30% F 9% F
Price / Cash Flow Ratio 21.08 4% F 21% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -168.01% 24% F 7% F
Return on Invested Capital -243.40% 25% F 0% N/A
Return on Assets -49.16% 32% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.51 50% F 27% F
Short Percent 22.00% 11% F 21% F
Beta 2.18 25% F 9% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector